BioCentury
ARTICLE | Company News

Celtrix, Insmed Pharmaceuticals deal

June 5, 2000 7:00 AM UTC

Insmed completed its acquisition of CTRX in a $140 million stock deal that valued CTRX at $1.55 per share (see BioCentury, Dec. 6, 1999). Insmed is developing therapies for metabolic and endocrine-rel...